Short Interest in Alto Neuroscience, Inc. (NYSE:ANRO) Drops By 21.0%

Alto Neuroscience, Inc. (NYSE:ANRO) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 2,198,907 shares, a decline of 21.0% from the December 15th total of 2,781,726 shares. Approximately 7.1% of the shares of the stock are sold short. Based on an average trading volume of 490,970 shares, the short-interest ratio is presently 4.5 days. Based on an average trading volume of 490,970 shares, the short-interest ratio is presently 4.5 days. Approximately 7.1% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

ANRO has been the subject of several research reports. Robert W. Baird increased their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Wall Street Zen upgraded Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. BTIG Research initiated coverage on Alto Neuroscience in a report on Monday, November 17th. They set a “buy” rating and a $27.00 price target for the company. Jefferies Financial Group lifted their price objective on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Finally, Chardan Capital upped their price objective on Alto Neuroscience from $15.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus target price of $26.33.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Bank of Montreal Can bought a new stake in Alto Neuroscience during the 2nd quarter valued at about $25,000. Ground Swell Capital LLC purchased a new position in shares of Alto Neuroscience during the second quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Alto Neuroscience during the second quarter valued at approximately $33,000. AlphaCore Capital LLC boosted its holdings in shares of Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after purchasing an additional 10,000 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of Alto Neuroscience in the first quarter valued at approximately $52,000.

Alto Neuroscience Trading Up 1.1%

ANRO traded up $0.19 on Friday, hitting $17.21. The company had a trading volume of 206,782 shares, compared to its average volume of 276,934. The business’s fifty day simple moving average is $15.66 and its 200 day simple moving average is $8.78. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $20.91. The company has a market cap of $534.74 million, a PE ratio of -7.52 and a beta of 2.78.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. Equities research analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.